Improvements in Plaque Psoriasis Associated with Calcipotriol/Betamethasone Aerosol Foam Treatment: A Post Hoc Analysis of Non-interventional Studies and Clinical Experience-Reference-Cited by-同舟云学术

Improvements in Plaque Psoriasis Associated with Calcipotriol/Betamethasone Aerosol Foam Treatment: A Post Hoc Analysis of Non-interventional Studies and Clinical Experience

Published:2024-02-15 Issue:3 Volume:14 Page:793-804
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Gerdes Sascha,Campanati Anna^ORCID,Ratzinger Gudrun,Halioua Bruno,Krogager Eeg Martin,Pesiridis Georgios,Jablonski Bernasconi Marie Y.,Lazaridou Elizabeth

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s13555-024-01108-0.pdf

Reference29 articles.

1. Rudnicka L, Olszewska M, Goldust M, et al. Efficacy and safety of different formulations of calcipotriol/betamethasone dipropionate in psoriasis: gel, foam, and ointment. J Clin Med. 2021;10(23):5589.

2. Papp KA, Thoning H, Gerdes S, et al. Matching-adjusted indirect comparison of efficacy outcomes in trials of calcipotriol plus betamethasone dipropionate foam and cream formulations for the treatment of plaque psoriasis. J Dermatolog Treat. 2022;33:1–9.

3. Jalili A, Calzavara-Pinton P, Kircik L, et al. Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: a post-hoc analysis of PSO-LONG. J Eur Acad Dermatol Venereol. 2022;36(1):60–7.

4. Lebwohl M, Kircik L, Lacour J-P, et al. Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). J Am Acad Dermatol. 2021;84(5):1269–77.

5. Gerdes S, Velasco M, Wu JJ, Hubo M, Veverka KA. Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: a review of real-world evidence (RWE). J Dermatolog Treat. 2021;32(8):883–93.